VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

Rhea-AI Summary

VYNE Therapeutics Inc. (Nasdaq: VYNE) will announce its third-quarter financial results for the period ending September 30, 2021, on November 10, 2021, before market opening. A conference call and webcast will take place at 8:30 AM ET to discuss the results and provide updates on corporate developments. VYNE aims to improve patient lives through innovative therapies for immuno-inflammatory conditions and has a pipeline including FMX114 for atopic dermatitis.

Positive

• VYNE is developing innovative therapies for high unmet medical needs in immuno-inflammatory conditions.
• The company has a proprietary pipeline, including FMX114 for atopic dermatitis.

Negative

• None.

BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call Details:
Wednesday, November 10th @ 8:30am Eastern Time
Toll Free:	855-327-6837
International:	631-891-4304
Conference ID:	10017178
Webcast:	https://themediaframe.com/mediaframe/webcast.html?webcastid=44cKOFEX

A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com after the conference call.

About VYNE Therapeutics Inc.

VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. VYNE is working to develop and commercialize a variety of therapies for major immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s unique and proprietary pipeline includes FMX114 for the treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors in both topical and oral forms for the treatment of major immuno-inflammatory conditions and rare skin diseases.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
Joseph Ranieri
LifeSci Advisors, LLC
617-430-7582
joer@lifesciadvisors.com

Tyler Zeronda
Chief Financial Officer
VYNE Therapeutics
908-458-9106
tyler.zeronda@vynetx.com

FAQ

When will VYNE Therapeutics report its Q3 financial results?

VYNE Therapeutics will report its Q3 financial results on November 10, 2021.

What time is the conference call for VYNE's Q3 results?

The conference call for VYNE's Q3 results will be held at 8:30 AM ET on November 10, 2021.

What is VYNE Therapeutics' stock symbol?

VYNE Therapeutics' stock symbol is VYNE.

What is VYNE's focus in terms of product development?

VYNE focuses on developing therapies for immuno-inflammatory conditions and rare skin diseases.